Poseida Therapeutics, Inc. (PSTX) Tops Q1 EPS by 16c

Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q1 EPS of ($0.45), $0.16 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $10.34 million versus the consensus estimate of $1.57 million.

For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Sunbelt Rentals Holdings, Inc. (SUNB) Reports Q2 EPS of $1.18